Chairman Jiang Xiaomeng proposed: "Four Focuses, Four Precautions" in 2017"
Release time:
2020-07-31
2016 annual summary commendation conference held on 1# April 20 , Jiang Xiaomeng, secretary of the party Committee and chairman of the group company, made a concluding speech, fully affirming the company's work in 2016 and putting forward the requirements of "four focuses and four precautions" for the enterprise management work in 2017 . In his concluding speech entitled "Continuously Improve the Competitiveness of the Organization and Make persistent efforts to Do All the Work in
", Jiang Xiaomeng said that in 2016 , the Group Company won the Silver Award of Zhejiang Industrial Award, the trademark "Peak" was recognized as a well-known trademark in China, and Yunnan Peak and Tianjin Natural Products Company achieved the best results in history, daye Peak has the lowest production cost and the best benefit in the region. Peak Pharmaceutical has made a good start in cooperation and upgrading. At the same time, Yunnan Peak, Daye Peak, Pharmaceutical Company, Natural Products Company and other diligent and continuous development teams have emerged. A large number of individuals and collectives who work hard without complaining are worthy of praise and affirmation. The ancients said that "good players seek momentum", "potential" is the situation, trend, situation, and development trend related to the overall situation; only those who seek momentum can stand high and see far. Only by being good at seeking the situation and then being good at taking advantage of the situation can we seize the first opportunity, find a new situation and create a new realm. New policies and new demands are forcing us to continue to reform and innovate. Managers at all levels must grasp the trend of industry and national policies in a timely manner, actively respond, follow the trend, and move in order to achieve better performance. In combination with the arrangement of the work in
in the general manager's report, Jiang Xiaomeng requires cadres and employees at all levels of the company to make great efforts to achieve "four focuses and four precautions", I .e. focusing on the market, focusing on costs, focusing on efficiency, focusing on development, and preventing and controlling risks, policy risks, security risks and financial risks. Focus on the market. Only by selling products for profit can the enterprise continue to produce and develop. For the peak, the two main businesses are in fully competitive industries. How can cement increase both volume and price, how can the pharmaceutical industry increase the sales volume of key products, how can enterprises make market recognition and customer recognition, and how to further expand business models and channels are all issues that need to be carefully studied. All enterprises should continue to expand the market, pay close attention to customer control and training, so that sales performance to a higher level.
Focus cost. Peak cement in recent years, the good performance, the core competitiveness is the cost. The company's other industries are also facing cost pressure, we must start from the procurement, process, management and other aspects of strict control, do everything possible to reduce costs, so as to enhance the market competitiveness of products.
Focus efficiency. There is still a considerable gap between the company's management efficiency, production efficiency and work efficiency compared with the advanced enterprises in the same industry. In recent years, good business performance has also made some managers inert and have a weak sense of urgency. Therefore, it is necessary to further strengthen the organizational structure optimization and post optimization to ensure that efficiency is given priority.
Focus on development. Only to maintain a healthy and stable development, development speed and efficiency of coordinated matching, enterprises can ensure long-term. If Jianfeng wants to become a century-old enterprise, it must further do a good job in development, and continue to be stronger, better, and bigger.
Jiang Xiaomeng pointed out that while enterprises achieve "four focuses" in the future development process, they must do a good job of "four precautions". The subordinate enterprises of the peak have many points and long lines, and they should rely on the system and internal control to manage the whole process, so as to ensure that the company's interests are not lost and prevent and control risks. All new policies related to enterprises and industries should be carefully studied and judged, and investment and technological transformation should be carried out according to the requirements to prevent policy risks. Safety is the eternal topic of enterprises. No matter how good the performance is, it will be empty, therefore, we must adhere to the "zero tolerance" attitude to grasp safety in production, prevent safety risks; do a good job in the planning and use of funds, ensure sufficient and smooth cash flow, strictly block fund loopholes, and prevent financial risks.
Jiang Xiaomeng hopes that managers at all levels will keep in mind the mission of "creating a century-old peak", always keep a clear mind, a rigorous style of acting, a work style of being public with one heart and one mind, put the interests of the enterprise first, give full play to the initiative of all levels of the team, carry forward positive energy, work together with high morale, and hand over a more beautiful answer in
. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31